Clinical Trial Update: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial comparing Lutetium-177 vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor versus AAA617 alone in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 vipivotide tetraxetan (AAA617) (lutetium-177 vipivotide tetraxetan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING